tbuckley/cabot-search huggingface dataset:
International Validity of the HOSPITAL Score to Predict 30-Day Potentially Avoidable Hospital Readmissions
Authors: Jacques D. Donzé, Mark V. Williams, Edmondo J. Robinson, Eyal Zimlichman, Drahomir Aujesky, Eduard E. Vasilevskis, Sunil Kripalani, Joshua P. Metlay, Tamara Wallington, Grant S. Fletcher, Andrew D. Auerbach, Jeffrey L. Schnipper
Journal: JAMA Internal Medicine (2016)

<h3>Importance</h3> Identification of patients at a high risk of potentially avoidable readmission allows hospitals to efficiently direct additional care transitions services to the patients most likely to benefit. <h3>Objective</h3> To externally validate the HOSPITAL score in an international multicenter study to assess its generalizability. <h3>Design, Setting, and Participants</h3> International retrospective cohort study of 117 065 adult patients consecutively discharged alive from the medical department of 9 large hospitals across 4 different countries between January 2011 and December 2011. Patients transferred to another acute care facility were excluded. <h3>Exposures</h3> The HOSPITAL score includes the following predictors at discharge: hemoglobin, discharge from an oncology service, sodium level, procedure during the index admission, index type of admission (urgent), number of admissions during the last 12 months, and length of stay. <h3>Main Outcomes and Measures</h3> 30-day potentially avoidable readmission to the index hospital using the SQLape algorithm. <h3>Results</h3> Overall, 117 065 adults consecutively discharged alive from a medical department between January 2011 and December 2011 were studied. Of all medical discharges, 16 992 of 117 065 (14.5%) were followed by a 30-day readmission, and 11 307 (9.7%) were followed by a 30-day potentially avoidable readmission. The discriminatory power of the HOSPITAL score to predict potentially avoidable readmission was good, with a C statistic of 0.72 (95% CI, 0.72-0.72). As in the derivation study, patients were classified into 3 risk categories: low (n = 73 031 [62.4%]), intermediate (n = 27 612 [23.6%]), and high risk (n = 16 422 [14.0%]). The estimated proportions of potentially avoidable readmission for each risk category matched the observed proportion, resulting in an excellent calibration (Pearson χ<sup>2</sup>test<i>P</i> = .89). <h3>Conclusions and Relevance</h3> The HOSPITAL score identified patients at high risk of 30-day potentially avoidable readmission with moderately high discrimination and excellent calibration when applied to a large international multicenter cohort of medical patients. This score has the potential to easily identify patients in need of more intensive transitional care interventions to prevent avoidable hospital readmissions.
Toxin Immunoassays andClostridium difficileInfection—Reply
Authors: Christopher R. Polage, Jay V. Solnick, Stuart H. Cohen
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Herniated lumbar disc disease in patients with malignancy.
Authors: R Goodkin, B I Carr, R G Perrin
Journal: Journal of Clinical Oncology (1987)

Six patients with cancer presented with signs and symptoms of a lumbar herniated disc syndrome due to a herniated lumbar disc. The differential diagnosis and literature are reviewed. In four of the six, the patients' complaints were attributed to the malignancy, with delay in diagnosis and institution of appropriate therapy. In two of the patients, treatment was administered for presumed spinal metastasis with radiation therapy and/or chemotherapy with castration before the correct diagnosis was made. Surgery was performed on all six patients confirming the diagnosis of a herniated lumbar disc at the involved level and relieving the patients' pain.
Key Questions in Marine Megafauna Movement Ecology
Authors: Graeme C. Hays, Luciana C. Ferreira, Ana M.M. Sequeira, Mark G. Meekan, Carlos M. Duarte, Helen Bailey, Fred Bailleul, W. Don Bowen, M. Julian Caley, Daniel P. Costa, Victor M. Eguíluz, Sabrina Fossette, Ari S. Friedlaender, Nick Gales, Adrian C. Gleiss, John Gunn, Rob Harcourt, Elliott L. Hazen, Michael R. Heithaus, Michelle Heupel, Kim Holland, Markus Horning, Ian Jonsen, Gerald L. Kooyman, Christopher G. Lowe, Peter T. Madsen, Helene Marsh, Richard A. Phillips, David Righton, Yan Ropert-Coudert, Katsufumi Sato, Scott A. Shaffer, Colin A. Simpfendorfer, David W. Sims, Gregory Skomal, Akinori Takahashi, Philip N. Trathan, Martin Wikelski, Jamie N. Womble, Michele Thums
Journal: Trends in Ecology & Evolution (2016)
340B Drug Pricing Program Reform
Authors: Warren H. Fong
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
The Error-Prone DNA Polymerase κ Promotes Temozolomide Resistance in Glioblastoma through Rad17-Dependent Activation of ATR-Chk1 Signaling
Authors: Chenghao Peng, Zhengxin Chen, Shuai Wang, Hong-Wei Wang, Wenjin Qiu, Lin Zhao, Ran Xu, Hui Luo, Yuanyuan Chen, Dan Chen, Yongping You, Ning Liu, Huibo Wang
Journal: Cancer Research (2016)

Abstract The acquisition of drug resistance is a persistent clinical problem limiting the successful treatment of human cancers, including glioblastoma (GBM). However, the molecular mechanisms by which initially chemoresponsive tumors develop therapeutic resistance remain poorly understood. In this study, we report that Pol κ, an error-prone polymerase that participates in translesion DNA synthesis, was significantly upregulated in GBM cell lines and tumor tissues following temozolomide treatment. Overexpression of Pol κ in temozolomide-sensitive GBM cells conferred resistance to temozolomide, whereas its inhibition markedly sensitized resistant cells to temozolomide in vitro and in orthotopic xenograft mouse models. Mechanistically, depletion of Pol κ disrupted homologous recombination (HR)-mediated repair and restart of stalled replication forks, impaired the activation of ATR-Chk1 signaling, and delayed cell-cycle re-entry and progression. Further investigation of the relationship between Pol κ and temozolomide revealed that Pol κ inactivation facilitated temozolomide-induced Rad17 ubiquitination and proteasomal degradation, subsequently silencing ATR-Chk1 signaling and leading to defective HR repair and the reversal of temozolomide resistance. Moreover, overexpression of Rad17 in Pol κ-depleted GBM cells restored HR efficiency, promoted the clearance of temozolomide-induced DNA breaks, and desensitized cells to the cytotoxic effects of temozolomide observed in the absence of Pol κ. Finally, we found that Pol κ overexpression correlated with poor prognosis in GBM patients undergoing temozolomide therapy. Collectively, our findings identify a potential mechanism by which GBM cells develop resistance to temozolomide and suggest that targeting the DNA damage tolerance pathway may be beneficial for overcoming resistance. Cancer Res; 76(8); 2340–53. ©2016 AACR.
Polyglycolic acid sheets for closure of refractory esophago-pulmonary fistula after esophagectomy
Authors: Noriko Matsuura, Noboru Hanaoka, Ryu Ishihara, Keijirou Sugimura, Masaaki Motoori, Hiroshi Miyata, Masahiko Yano
Journal: Endoscopy (2016)

Anastomotic leakage, which is one of the complications of esophagectomy, sometimes causes a refractory fistula despite conservative therapy [1]. Polyglycolic acid (PGA) sheets (Neoveil; Gunze, Kyoto, Japan), a suture reinforcement material that is absorbed within 4 – 15 weeks, have been used in many fields of open and endoscopic surgery [2] [3] to prevent delayed perforation [4] [5]. Here we report successful closure of a refractory esophago-pulmonary fistula using PGA sheets.
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety
Authors: U.A. Matulonis, R.T. Penson, S.M. Domchek, B. Kaufman, R. Shapira-Frommer, M.W. Audeh, S. Kaye, L.R. Molife, K.A. Gelmon, J.D. Robertson, H. Mann, T.W. Ho, R.L. Coleman
Journal: Annals of Oncology (2016)
Recombinant AAV Integration Is Not Associated With Hepatic Genotoxicity in Nonhuman Primates and Patients
Authors: Irene Gil-Farina, Raffaele Fronza, Christine Kaeppel, Esperanza Lopez-Franco, Valerie Ferreira, Delia D'Avola, Alberto Benito, Jesus Prieto, Harald Petry, Gloria Gonzalez-Aseguinolaza, Manfred Schmidt
Journal: Molecular Therapy (2016)

Recombinant adeno-associated viral vectors (rAAV) currently constitute a real therapeutic strategy for the sustained correction of diverse genetic conditions. Though a wealth of preclinical and clinical studies have been conducted with rAAV, the oncogenic potential of these vectors is still controversial, particularly when considering liver-directed gene therapy. Few preclinical studies and the recent discovery of incomplete wild-type AAV2 genomes integrated in human hepatocellular carcinoma biopsies have raised concerns on rAAV safety. In the present study, we have characterized the integration of both complete and partial rAAV2/5 genomes in nonhuman primate tissues and clinical liver biopsies from a trial aimed to treat acute intermittent porphyria. We applied a new multiplex linear amplification-mediated polymerase chain reaction (PCR) assay capable of detecting integration events that are originated throughout the rAAV genome. The integration rate was low both in nonhuman primates and patient's samples. Importantly, no integration clusters or events were found in genes previously reported to link rAAV integration with hepatocellular carcinoma development, thus showing the absence of genotoxicity of a systemically administered rAAV2/5 in a large animal model and in the clinical context.
Abstract 16828: Prognostic Value of Location of Occurrence in Sudden Cardiac Arrest During Sports
Authors: Eloi Marijon, Wulfran Bougouin, Lionel Lamhaut, Nicole Karam, Marie Cecile Perier, Muriel Tafflet, Nordine Benameur, Florence Dumas, Hazrije Mustafic, Jean-Philippe Empana, David Celermajer, Xavier Jouven
Journal: Circulation (2013)

Background: No data aimed to evaluate characteristics and outcomes of sudden cardiac arrest (SCA) according to the location of occurrence (sports facilities vs. in the field). However, these inform...
Surgical Proficiency Gain and Survival After Esophagectomy for Cancer
Authors: Sheraz R. Markar, Hugh Mackenzie, Pernilla Lagergren, George B. Hanna, Jesper Lagergren
Journal: Journal of Clinical Oncology (2016)

We aimed to identify the presence and length of esophagectomy proficiency gain curves in terms of short- and long-term mortality for esophageal cancer.Patients who underwent esophagectomy for esophageal cancer between 1987 and 2010 with follow-up until 2014 were identified from a well-established, population-based, nationwide Swedish cohort study. Proficiency gain curves were created by using risk-adjusted cumulative sum analysis for 30-day, 90-day, 1-year, 3-year, and 5-year all-cause and disease-specific mortality measures. Similarly, the proficiency gain curves for lymph node harvest, resection margin status, and reoperation incidence were assessed as performance-contributing factors to the observed changes in long-term survival.Esophagectomies in 1,821 patients with esophageal cancer were conducted by 139 surgeons. The change-point in proficiency gain curve for all-cause 30-day mortality was early, at 15 cases, when mortality decreased from 7.9% to 3.1% (P < .001). Later change-points, which ranged from 35 to 59 cases, were observed for 1-, 3- and 5-year mortality rates, for which all-cause mortality decreased from 34.9% to 27.7% (P = .011), from 47.4% to 41.5% (P = .049), and from 31.4% to 19.1% (P = .009), respectively. Similar change-points were observed in disease-specific mortality at 1 and 3 years. There was a continuous increase in lymph node harvest, which did not plateau. Also, change-points were observed for resection margin with tumor involvement at 17 cases, with a reduction from 20.9% to 15.2% (P = .004), and for reoperation rate at 55 cases, with a reduction from 12.6% to 5.0% (P < .001).The gain of proficiency in esophagectomy for cancer is associated with measurable changes in short- and long-term mortality results. These findings indicate a need for structured national training and mentorship programs for esophageal cancer surgery.
Rhinovirus Infection Results in Increased and More Persistent Dysregulation of Gene Expression
Authors: Huyen-Tran Nguyen, Peter W. Heymann, Mark Lindsey, Umasundari Sivaprasad, Mario Medvedovic, Naim Mahi, Thomas A.E. Platts-Mills, Ronald B. Turner, John W. Steinke, Judith A. Woodfolk, Larry Borish, Gurjit K. Khurana Hershey
Journal: Journal of Allergy and Clinical Immunology (2016)
Type 2M:Milwaukee-1 von Willebrand disease: an in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to platelets
Authors: DJ Mancuso, PA Kroner, PA Christopherson, EA Vokac, JC Gill, RR Montgomery
Journal: Blood (1996)
Preliminary safety and efficacy results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube
Authors: T. J. Herzog, N. M. Spirtos, J. F. Hines, P. S. Braly, M. Bell, A. A. Secord, P. Rose, B. J. Monk, E. Soltes-Rak, B. H. Childs
Journal: Journal of Clinical Oncology (2007)

5518 Background: Objectives: Determine safety and estimate efficacy of a novel taxane/platinum chemotherapy (CTX) doublet in conjunction with bevacizumab, as first-line treatment of advanced cancer of the ovary, peritoneum or fallopian tube (FT), after initial debulking surgery. Methods: Treatment: 6 cycles of oxaliplatin (O) (85 mg/m 2 ), docetaxel (D) (75 mg/m 2 ) and bevacizumab (B) (15 mg/kg) Q3W, followed by maintenance B (15 mg/kg Q3W) to complete one year of therapy. Pts were treated until disease progression, unacceptable toxicity, prolonged treatment delay, death, or refusal to continue on study. The primary efficacy endpoint is PFS at 12 months. Results: As of 30 Nov 06, 59 pts (median age 58) were enrolled. Primary sites of disease included 47 ovary, 7 peritoneum, 4 FT. Tumors were mostly poorly differentiated (70%) with a serous adenocarcinoma initial pathology type (81%). Most pts were stage IIIC (40) or IV (17). 64% of pts. were optimally debulked. GOG PS was 0–1 in 56 pts. 58 pts were treated with at least one cycle of CTX. 22 pts. completed six cycles of CTX + B; 14 of these have begun B maintenance Rx. Safety data in available on a total of 283 patient-cycles. Of the 57 pts. with adverse event (AE) data available, 31 (54%) reported at least one grade 3–4 AE, 9 (16%) at least one serious AE (SAE), 54 at least one AE related to CTX (O or D), and 45 reported at least one AE related to B. There have been 8 SAEs related to CTX (O or D): febrile neutropenia (FN) (2), chest pain (1), dehydration (1), lymphopenia (1), neutropenia (1), peripheral sensory neuropathy (PSN) (1), palpitations (1). There have been 7 SAEs related to B: chest pain, colonic fistula, dehydration, FN, palpitations, PSN, vertigo (1 each). There were no B-associated colonic perforations. Of the 59 subjects, 31 (53%) had measurable disease at baseline. One of 31 patients has confirmed progression of disease. Conclusions: This preliminary data supports feasibility of this novel regimen, with an acceptable safety profile. As of December 2006, 75 patients have been enrolled. Updated safety and preliminary efficacy (RR) data will be presented. No significant financial relationships to disclose.
In-class didactic versus self-directed teaching of the probe-based confocal laser endomicroscopy (pCLE) criteria for Barrett’s esophagus
Authors: Fadi Rzouq, Prashanth Vennalaganti, Kavous Pakseresht, Vijay Kanakadandi, Sravanthi Parasa, Sharad Mathur, Benjamin Alsop, Benjamin Hornung, Neil Gupta, Prateek Sharma
Journal: Endoscopy (2015)

<b>Background and aims: </b>Optimal teaching methods for disease recognition using probe-based confocal laser endomicroscopy (pCLE) have not been developed. Our aim was to compare in-class didactic teaching vs. self-directed teaching of Barrett’s neoplasia diagnosis using pCLE. <b>Methods: </b>This randomized controlled trial was conducted at a tertiary academic center. Study participants with no prior pCLE experience were randomized to in-class didactic (group 1) or self-directed teaching groups (group 2). For group 1, an expert conducted a classroom teaching session using standardized educational material. Participants in group 2 were provided with the same material on an audio PowerPoint. After initial training, all participants graded an initial set of 20 pCLE videos and reviewed correct responses with the expert (group 1) or on audio PowerPoint (group 2). Finally, all participants completed interpretations of a further 40 videos. <b>Results: </b>Eighteen trainees (8 medical students, 10 gastroenterology trainees) participated in the study. Overall diagnostic accuracy for neoplasia prediction by pCLE was 77 % (95 % confidence interval [CI] 74.0 % – 79.2 %); of predictions made with high confidence (53 %), the accuracy was 85 % (95 %CI 81.8 % – 87.8 %). The overall accuracy and interobserver agreement was significantly higher in group 1 than in group 2 for all predictions (80.4 % vs. 73 %; <i>P</i> = 0.005) and for high confidence predictions (90 % vs. 80 %; <i>P</i> < 0.001). Following feedback (after the initial 20 videos), the overall accuracy improved from 73 % to 79 % (<i>P</i> = 0.04), mainly driven by a significant improvement in group 1 (74 % to 84 %; <i>P</i> < 0.01). Accuracy of prediction significantly improved with time in endoscopy training (72 % students, 77 % FY1, 82 % FY2, and 85 % FY3; <i>P</i> = 0.003). <b>Conclusion: </b>For novice trainees, in-class didactic teaching enables significantly better recognition of the pCLE features of Barrett’s esophagus than self-directed teaching. The in-class didactic group had a shorter learning curve and were able to achieve 90 % accuracy for their high confidence predictions.
Abstract 14102: Associations Between Thrombin Generation and the Risk of Cardiovascular and Cerebrovascular Events in the Elderly: Results From the PROSPER Study
Authors: Rinske Loeffen, Kristien Winckers, Ian Ford, J.W. Jukema, Michele Robertson, David J Stott, Henri M Spronk, Hugo ten Cate, Gordon D Lowe
Journal: Circulation (2013)

Introduction: Studies suggest a contribution of hypercoagulability to the pathophysiology of atherosclerosis and -thrombosis. As thrombin fulfills a central role in coagulation and links to several...
Incidence of Diabetes in Colorectal Cancer Survivors
Authors: Simron Singh, Craig C. Earle, Sandy J. Bae, Hadas D. Fischer, Lingsong Yun, Peter C. Austin, Paula A. Rochon, Geoffrey M. Anderson, Lorraine Lipscombe
Journal: JNCI Journal of the National Cancer Institute (2016)

A higher risk of colorectal cancer (CRC) in patients with diabetes has been well documented. However, little is known regarding diabetes incidence in CRC survivors. This may have substantial impact on CRC survivorship care as well as enhancing the understanding of the interplay between the two diseases. We explored whether the incidence of diabetes was higher among patients with CRC than matched control subjects. Using population-based data from Ontario, Canada, we generated a dataset comprising 39 707 incident CRC cases and 198 535 age- and sex-matched control subjects (1:5) dating from April 2002 to March 2010. We used cause-specific hazard models to estimate the hazard ratios (HRs) for diabetes overall and in subgroups stratified by receipt of systemic chemotherapy, diagnosis of metastatic disease, and site of cancer. During a mean follow-up of 4.81 years, the association between CRC and diabetes varied: The rate of developing diabetes was 53% higher among CRC patients compared with control subjects in the first year postdiagnosis (HR = 1.53, 95% confidence interval [CI] = 1.42 to 1.64) and remained increased by 19% in the fifth year postdiagnosis (HR = 1.19, 95% CI = 1.05 to 1.35). Findings were similar in subgroups of patients who had colon cancer, received systemic chemotherapy, or had no evidence of metastasis. We found that CRC patients were statistically significantly more likely to develop subsequent diabetes than persons without CRC for up to five years after the diagnosis. Our study suggests that active screening and counseling regarding modifiable risk factors may be warranted in this high-risk group.
Poster Exhibition : Comparison of Human Mesenchymal Stem Cells Obtained from Placenta, Bone Marrow and Umbilical Cord Blood Into Hepatogenic Differentiation (초)
Authors: Joung Ah Park, Gi Dae Kim, Sung Tae Park, Jung Hyun Kwon, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Il Hoan Oh, Kun Ho Yoon, Si Hyun Bae
Journal: Clinical and Molecular Hepatology (2009)